GloboScience

Executive Summary

GloboScience is a San Francisco-based regulatory strategy and product development consulting firm serving the life sciences sector. Founded in 2019, the company specializes in creating novel regulatory pathways for complex, precedent-lacking medical products, with a particular focus on rare diseases and advanced therapies. Its end-to-end consulting spans therapeutics, biologics, devices, and combination products, guiding clients from concept through commercialization. By positioning itself at the intersection of innovation and regulation, GloboScience addresses a critical need for expertise in navigating evolving FDA frameworks and global regulatory standards. The firm is well-positioned to benefit from the growing complexity of drug and device development, especially in gene therapies, cell therapies, and personalized medicine. While the consulting market is competitive, GloboScience's niche focus on rare diseases and novel regulatory strategies provides differentiation. The company's growth is tied to client successes and new engagements, with potential tailwinds from increasing R&D spending and regulatory changes. However, as a private consulting firm, financial metrics and specific milestones are not publicly disclosed, making forward-looking assessment reliant on industry trends and inferred catalysts.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a top-20 pharmaceutical company40% success
• 2026Expansion of regulatory consulting services into European markets60% success
• Q4 2026Client receives first FDA approval for a gene therapy using GloboScience's regulatory pathway30% success